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A number of small proteins have been purified and 
shown to partially replace the serum requirement for 
the growth of cells in culture [l-3]. Generally the 
response to these growth factors has been quantified 
as either a stimulus of DNA synthesis or an increase 
in cell number fl-71. Although protein synthesis i  
stimulated, s&nit&ant increases are not readily mea- 
sured until several hours after addition of the growth 
factor [4]. Since a decrease in the rate of intracellular 
protein degradation can contribute to protein accu- 
mulation equally well as a stimulus in protein syn- 
thesis, we have examined rates-of protein breakdown 
after the addition of purified growth factors to 
various cell lines. The experiments show a consistent 
and marked inhibition of protein degradation of
physioIo~c~ concentrations of insulin, EGF, FGF, 
IGF-I and IGF-II in cells known to be responsive to 
these factors. 
2, Materials and methods 
Fetal calf serum was obtained from Common- 
wealth Serum Laboratories, Melbourne (lot 171-2); 
insulin (Actrapid} from Novo Industri, Copenh~en; 
EGF and FGF from Collaborative Research, Waltham, 
MA; IGF-f and IGF-II from Dr R. E. Humbel, Univer- 
sity of Zurich. L[4,5-3H]leucine (40-60 Cifmmol) 
d~~re~ja~o~s: EGF, epidermai growth factor; FGF, fibroblast 
growth factor; HZ-f, IGF-II, churn-1~~ growth factors I 
and II 
was from either New England Nuclear or The Radio- 
chemical Centre, Amersham. Sources of culture 
media have been described in 181. 
The sources of the different cell lines were: 
MHr Cl hepatoma, Swiss 3T3 fibroblasts and JT12-3 
fibroblasts, American Type Culture Collection, Rock- 
ville, MD; IMR-90 human ~broblasts.and AG-2804 
transformed human fibroblasts, Institute for Medical 
Research, Camden, NJ; Balb/c 3T3 and SV40-trans- 
formed Balbjc 3T3 fibroblasts, Dr Stuart Aaronson, 
National Cancer Institute, Bethesda, MD; HTC hepa- 
toma, Dr W. D. Wicks, Department of Pharmacol- 
ogy, University of Colorado, CO; H35 hepatoma, Dr 
Joyce Becker, University of Wisconsin, Madison, WI; 
BEN bronchial carcinoma, rat osteogenic sarcoma nd 
newborn rat calvarial osteoblasts, Drs T. J. Martin and 
N. C. Partridge, Repatriation General Hospital, West 
Heidelberg, VIC 3077; NRK wild type and NRK-442, 
Dr E. M. Scolnick, National Cancer Institute, Bethesda, 
MD. Primary cultures of adult rat hepato~~es were 
prepared from tissue perfused with coliagenase [9]; 
adipose fibroblasts were from rat epididymal tissue 
flO] and chick embryo line fibroblasts from 9day 
embryos fI l]_ The liver line was an e~i~e~~~l~e cell 
line derived from a monolayer of parenchymal cells 
which had been prepared from a lo-day-old rat by 
collagenaseltrypsin digestion. 
Confluent cell monolayers in Costar 24-w& dishes 
were incubated for 16 h in Dulbecco-modified mini- 
mal essential medium containing 10% fetal calf serum, 
penicillin G (60 mg/l), streptomycin sulphate (100 
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mgjl), gentamycin (50 mgfl) and 1 &i [ 3H] leucine/~ 
withunlabelled leucine omitted. This labelling medium 
was removed, the monolayers washed twice with 
‘degradation medium’ (minimal essential medium 
contain~g the antibiotics listed above, 2 mM leucine, 
0.1% bovine serum albumin and 20 mMN-Tris [hydrox- 
ymethyl] methyl-2-aminoethane sulphonic acid) and 
a further 1 ml of this medium added to each well and 
left for 3 h to permit he breakdo~ of unstable pro- 
teins. Subsequently this medium was replaced with 
1 ml of similar medium‘with serum or growth factors 
added at the concentrations indicated. After 4 h por- 
tions of the medium were taken for the determination 
of trichloroacetic acid-soluble and -insoluble radio- 
activity and the monolayer was dissolved in 1 ml 
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Fig. 1. Concentration dependence of ICE-1 inhibition of 
protein degradation. Values are means * SEM for 6 determi- 
nations at each IGF-I concentration. The cell lines used were 
calvarial osteoblast-like cells fo), a liver line (a), MH,C, (A), 
H35 (e), osteogenic sarcoma (‘I), HTC (o), AG-2804 (m) and 
BEN (0). 
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Fig.2. rnhibition of protein degradation produced by growth 
factors added to IMR-90 cells. The growth factors used were 
insulin (a), FGF (o), ICE-1 (I), IGF-II (A) and EGF (0). 
Values are means c SEM for 6- 12 determinations at each 
concentration and are expressed as percentages of the degra- 
dation measured in ‘degradation medium’. 
0.1 N NaOH containing 0.5% Triton Xl 00. The per- 
cent degradation iscalculated at IOO-times the radio- 
activity in the medium trichloroacetic acid-soluble 
fraction divided by the total radioactivity in each well. 
Appropriate zero time values (typically O.l-0.2% 
de~adation} are subtracted. 
3. Results and discussion 
Concentration effects of IGF-I on protein break- 
down are shown in fig.1. Inhibition of the pathway 
by lo-* M IGF-I occurred in all 8 of the cell lines 
tested, with effects ranging from a 5% (BEN carci- 
noma) to a 30% (AG-2804) reduction. The cells 
appear to fall into two groups when sensitivity of the 
growth factor is considered. Thus calvarial osteoblasts, 
the liver line, BEN bronchial carcinoma s well as the 
MHiCi and H35 hepatomas re not affected at lo-” M 
IGF-I but show inhibition at higher concentrations. A 
sensitivity comp~dble to this group of cell lines has 
been described for DNA synthesis in chick embryo 
fibroblasts [6]. The response with HTC hepatoma, 
AG-2804 transformed human fibroblasts and the 
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osteogenic sarcoma is displaced by -2 orders of 
magnitude towards lower IGF-I concentrations. Half- 
maximal effects are found in these cells at 
-3 X 10-l’ M. This ‘sensitive’ group contains only 
transformed cells whereas the first group comprises 
both contact-inhibited and transformed cells. IGF-I 
has been reported present at 2 X fOq8 M in normal 
human serum [6], a concentration which would 
markedly inhibit protein degradation i all the cell 
lines shown in fig.1 except for the BEN carcinoma. 
Mitogenic effects in fibroblasts have been described 
after addition of EGF [ 1 ,S], FGF [2,7], IGF-I and 
IGF-II [6] as well as high concentrations of insulin [7]. 
Measurements with IMR-90, a human diploid fibro- 
blast line [ 121, show inhibition of protein break- 
down by all these growth factors (fig.2). Half-maximal 
effects are seen at approx. 10-l’ M EGF, 5 X lo-” M 
FGF, lo-’ M IGF-I, 2 X lo-’ M IGF-II and IO-* M 
insulin. The maghitude of the responses also differs, 
although our inability to test some of the growth 
factors at >lOa M precludes comparison of maximal 
effects. With the exception of studies howing inhibi- 
tion of protein breakdown by insulin in several cell 
lines [8,9,13;14], the only experiments where purified 
growth factors have been tested on the pathway have 
been those in [ 151 where 16% inhibition by lo-* M 
FGF in rat embryo fibroblasts was found. The 
response was potentiated when insulin and dexameth- 
asone were added with FGF. 
A summary of growth factor effects on protein 
degradation for 19 cell lines is given in table 1. For 
simplicity the data are shown as the percentage inhi- 
bition of degradation produced when the growth 
factor was added at 10S8 M. Effects with a single 
batch of fetal calf serum are listed for comparison for 
12 of the lines. It is evident hat serum, IGF-I and 
Table 1 
Inhibition of protein degradation by growth factors 
Cell line Percent inhibition of protein degradation produced by 
Serum Insulin EGF FGF IGF-I IGF-II 
Contact-inhibited 
Hepatocytes 17 20 7 
Liver line 30 <5 24 
IMR-90 19 12 26 
Balb/c 3T3 28 15 
Swiss 3T3 24 8 
Chick embryo fibroblasts 22 7 
Adipose fibroblasts 24 9 7 
NRK-wild type 8 13 
Calvarial osteoblasts 28 <5 5 
Transformed 
H35 
HTC 
MI&C, 
tr-IMR 
AG-2804 
SV40-3T3 
3T12-3 
NRK-442 
BEN 
Osteogenic sarcoma 
27 
35 
24 
24 
34 
13 
13 
30 <5 
27 <5 
25 <5 
19 <5 
22 8 
19 14 
16 10 
6 <5 
15 <5 
6 5 
5 13 
14 8 
13 25 19 
26 
16 
<5 
<5 
16 12 
29 33 
31 29 
20 23 
38 32 
<5 33 26 
12 
11 
S 
10 
9 
10 
Protein degradation was determined as in section 2. Data are expressed as percen- 
tage effects produced by the growth factors as compared to ‘degradation medium’. 
Fetal calf serum was added to give a 20% (v/v) solution; insulin, EGF, FGF, IGF-I 
and IGF-II were all added at lo-* M 
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IGF-II inhibited protein degradation in every cell line 
tested, while insulin effects were obtained in all cells 
except a liver line and calvarial osteoblasts. Our 
unpublished experiments have shown extremely low 
binding of 1251-labelled insulin in these two lines. Sig- 
nificant inhibition of protein breakdown by EGF 
occurred in all the contact-inhibited lines with the 
largest responses occurring in IMR-90 fibroblasts, the 
liver line and Balb/c 3T3 cells. Smaller effects of EGF 
were noted in both ceil lines that had been trans- 
formed with SV40 virus (AG-2804, SV40-3T3), 
3T12-3 cells and the osteogenic sarcoma. However, 
none of the hepatomas showed a response to EGF. 
Protein breakdown was inhibited by FGF in three of 
the contact-inhibited fibroblasts and in SV40-3T3 
and 3T12-3 mouse fibroblasts. 
Any common mechanism accounting for the inhibi- 
tion of protein breakdown by growth factors is prob- 
ably dependent on their binding to surface receptors. 
Thus all cell lines tested in which protein breakdown is 
inhibited by EGF or insulin have high affinity recep- 
tors for these agents (F. J. B., S. E. K., J. B. B., 
J. M. G., S. S. C. W., N. C. Partridge, T. J. Martin, 
unpublished). The post-receptor mechanism for insulin 
action on protein breakdown apparently involves a 
reduction in the number and size of autophagic 
vacuoles [ 16-181. Since we have no information on 
the proportion of lysosomes or autophagic vacuoles 
in cells exposed to growth factors other than insulin, 
an extension of this concept to all growth factors is 
perhaps premature. However, in measurements on 
Balb/c 3T3 and IMR-90 cells, the addition of either 
EGF or FGF together with concentrations of insulin 
that produced maximal inhibitions of protein break- 
down gives no extra effect (S. E. K., F. J. B., J. B. B., 
and J. M. G., unpublished). This is consistent with all 
three factors acting via a common mechanism. 
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